IL149495A0 - Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy - Google Patents

Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy

Info

Publication number
IL149495A0
IL149495A0 IL14949500A IL14949500A IL149495A0 IL 149495 A0 IL149495 A0 IL 149495A0 IL 14949500 A IL14949500 A IL 14949500A IL 14949500 A IL14949500 A IL 14949500A IL 149495 A0 IL149495 A0 IL 149495A0
Authority
IL
Israel
Prior art keywords
therapy
receptor antagonist
pharmaceutical formulations
thrombotic agent
thrombotic
Prior art date
Application number
IL14949500A
Other languages
English (en)
Original Assignee
Astrazeneca Ab Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Astrazeneca Ab filed Critical Astrazeneca Ab Astrazeneca Ab
Publication of IL149495A0 publication Critical patent/IL149495A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14949500A 1999-12-01 2000-11-29 Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy IL149495A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations
PCT/SE2000/002378 WO2001039781A1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
IL149495A0 true IL149495A0 (en) 2004-03-28

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14949500A IL149495A0 (en) 1999-12-01 2000-11-29 Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy

Country Status (32)

Country Link
US (2) US20030032618A1 (cs)
EP (2) EP1237559B1 (cs)
JP (1) JP2003515565A (cs)
KR (1) KR100785953B1 (cs)
CN (1) CN1402639A (cs)
AR (1) AR033658A1 (cs)
AT (1) ATE332698T1 (cs)
AU (1) AU781691B2 (cs)
BR (1) BR0016043A (cs)
CA (1) CA2391161C (cs)
CO (1) CO5271717A1 (cs)
CY (1) CY1105211T1 (cs)
CZ (1) CZ300925B6 (cs)
DE (1) DE60029340T2 (cs)
DK (1) DK1237559T3 (cs)
EE (1) EE05127B1 (cs)
ES (1) ES2267591T3 (cs)
HU (1) HU230890B1 (cs)
IL (1) IL149495A0 (cs)
IS (1) IS2841B (cs)
MX (1) MXPA02004871A (cs)
MY (1) MY128896A (cs)
NO (1) NO331215B1 (cs)
NZ (2) NZ530058A (cs)
PT (1) PT1237559E (cs)
RU (1) RU2242232C2 (cs)
SE (1) SE9904377D0 (cs)
SI (1) SI1237559T1 (cs)
SK (1) SK288707B6 (cs)
TW (1) TWI251491B (cs)
WO (1) WO2001039781A1 (cs)
ZA (1) ZA200203707B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
US20080226579A1 (en) * 2005-09-21 2008-09-18 Chong Kun Dang Pharmaceutical Corp. Novel Resinate Complex of S-Clopidogrel and Production Method Thereof
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PL2498731T3 (pl) 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
JP6247708B2 (ja) 2013-03-09 2017-12-13 キエージィ ファーマチェウティチ エス．ペー．アー． 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
CN110740736A (zh) 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
ATE127808T1 (de) * 1991-04-06 1995-09-15 Fisons Plc Atp-analogen.
CN1042430C (zh) * 1993-02-10 1999-03-10 英国阿斯特拉药品有限公司 N－烷基－2－取代的atp类似物、其制备方法和用途
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2226758A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
JPWO2005007191A1 (ja) * 2003-07-16 2006-08-31 協和醗酵工業株式会社 医薬組成物

Also Published As

Publication number Publication date
AU1910901A (en) 2001-06-12
HUP0203585A3 (en) 2005-01-28
SK7502002A3 (en) 2003-02-04
NZ530058A (en) 2005-04-29
NZ518904A (en) 2004-02-27
PT1237559E (pt) 2006-10-31
EP1719526A3 (en) 2007-04-25
SI1237559T1 (sl) 2007-02-28
NO20022606L (no) 2002-07-11
NO20022606D0 (no) 2002-05-31
CY1105211T1 (el) 2010-03-03
CO5271717A1 (es) 2003-04-30
MY128896A (en) 2007-02-28
US20060270607A1 (en) 2006-11-30
EP1719526A2 (en) 2006-11-08
PL355841A1 (en) 2004-05-17
KR100785953B1 (ko) 2007-12-14
CA2391161A1 (en) 2001-06-07
AR033658A1 (es) 2004-01-07
HK1047893A1 (en) 2003-03-14
RU2002117296A (ru) 2004-01-20
CZ20021887A3 (cs) 2002-11-13
HU230890B1 (hu) 2018-12-28
SK288707B6 (sk) 2019-10-02
ZA200203707B (en) 2003-10-29
KR20020069201A (ko) 2002-08-29
EE05127B1 (et) 2009-02-16
RU2242232C2 (ru) 2004-12-20
ATE332698T1 (de) 2006-08-15
ES2267591T3 (es) 2007-03-16
EP1237559A1 (en) 2002-09-11
HUP0203585A2 (hu) 2003-03-28
DE60029340D1 (de) 2006-08-24
WO2001039781A1 (en) 2001-06-07
EE200200271A (et) 2003-06-16
IS2841B (is) 2013-08-15
DE60029340T2 (de) 2007-07-19
EP1237559B1 (en) 2006-07-12
CA2391161C (en) 2010-10-05
SE9904377D0 (sv) 1999-12-01
CZ300925B6 (cs) 2009-09-09
CN1402639A (zh) 2003-03-12
TWI251491B (en) 2006-03-21
US20030032618A1 (en) 2003-02-13
NO331215B1 (no) 2011-11-07
MXPA02004871A (es) 2002-08-30
AU781691B2 (en) 2005-06-09
JP2003515565A (ja) 2003-05-07
DK1237559T3 (da) 2006-10-30
BR0016043A (pt) 2002-07-23
IS6398A (is) 2002-05-27

Similar Documents

Publication Publication Date Title
IL149495A0 (en) Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
HUP0203638A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
SI1267880T1 (sl) Formulacija z nizko dozo entekavirja in uporaba
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
AU7002501A (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
IL158780A0 (en) Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis
EP1207812A4 (en) DEVICE FOR GUIDING IMPLANT AND ADMINISTERING AN AGENT
IL145715A0 (en) Formulation arrays and use thereof
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
AU1164601A (en) Therapeutic use and formulation
HUP0203121A3 (en) Pharmaceutical composition containing substituted benzimidazoles and its use
HUP0203627A3 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical compositions comprising them
EP1292309A4 (en) PROPHYLACTIC AND THERAPEUTIC USE OF OLTIPRAZ AS AN AGENT AGAINST FIBROSIS AND CIRRUSH OF THE LIVER AND PHARMACEUTICAL COMPOSITION CONTAINING OLTIPRAZ
PL339848A1 (en) Therapeutic agent against hypephosphataemia
PL363048A1 (en) Azabicyclic derivatives and their therapeutic use
HUP0003074A3 (en) Pharmaceutical composition comprising ssri and betha-blocking agent
HUP0301119A3 (en) Biologically active agent and drug
EP1154783A4 (en) RELAXIN-CONTAINING MEDICAMENTS AND ITS USE
EP1221945A4 (en) METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
GB9926528D0 (en) Therapeutic use and formulation
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
GB9906124D0 (en) Therapeutic agent